Results 211 to 220 of about 310,012 (268)

Activation of Metal Complexes With Ultrasound Waves for Targeted Anticancer Therapy

Angewandte Chemie International Edition, EarlyView.
Ultrasound enables non‐invasive activation of metal‐based therapeutics deep within tumors. Acoustic cavitation can drive sonodynamic reactive oxygen species generation or mechanochemical metal–ligand bond dissociation, enabling controlled release of bioactive payloads.
Félix Grosjean, Nicolás Montesdeoca, Gilles Berger, Johannes Karges   +3 more
wiley   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Correction to "HLA-B Associates With Distinct Disease Expression in Juvenile Spondyloarthritis: A Retrospective Cohort Study". [PDF]

ACR Open Rheumatol
europepmc   +1 more source

Therapeutic plasma exchange in paediatric ANCA-associated vasculitis: a multicentre real-world experience. [PDF]

Rheumatology (Oxford)
Menentoğlu B, Küçükali B, Demirkan FG, Kılbaş G, Türkmen Ş, Küçük E, Işıklar Ekici M, Alkaya A, Menentoğlu ME, Çakmak F, Akgün Ö, Şevketoğlu E, Öztürk K, Özdel S, Türkuçar S, Yüksel S, Acar BÇ, Sözeri B, Bakkaloğlu SA, Aktay Ayaz N.   +19 more
europepmc   +1 more source

CD14 Plays a Critical Role in Pain and Inflammation Across Multiple Models of Post‐traumatic Osteoarthritis

Arthritis &Rheumatology, EarlyView.
Objective We employed global genetic deletion of CD14 and intra‐articular CD14 blockade across multiple murine osteoarthritis (OA) models that vary in severity of pathology and rate of progression to test the hypothesis that CD14 inhibition attenuates synovial inflammation and associated pain during disease progression.
Kevin G. Burt, Sanique M. South, Natalie S. Adamczyk, Vu Nguyen, Shingo Ishihara, Cheng Zhou, Kate L. Sharp, Sung Y. Kim, Anna E. Rapp, Baofeng Hu, Lance A. Murphy, Li‐Yin Hung, De'Broski Herbert, Joshua F. Baker, Robert L. Mauck, Timothy M. Griffin, Anne‐Marie Malfait, Rachel E. Miller, Carla R. Scanzello   +18 more
wiley   +1 more source

Correction to "Exploring the Association Between Systemic Lupus Erythematosus and High-Density Lipoproteins: A Systematic Review and Meta-Analysis". [PDF]

ACR Open Rheumatol
europepmc   +1 more source

Clinical characteristics and outcomes of paediatric chronic non-bacterial osteomyelitis: a retrospective cohort study with focus on zoledronic acid. [PDF]

Rheumatology (Oxford)
Herman Y, Akikusa JD, Jones J, Tiller GM, Munro JE, Simm P, Zacharin M, Liyanage N, Varma N, Renton WD.   +9 more
europepmc   +1 more source

Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes, Luisa R. Monne, Sara Comdühr, Fynn Gerlach, Hanna Grasshoff, Alexander Dübbers, Antje Müller, Alexander Scheffold, Gabriela Riemekasten, Reza Akbarzadeh, Jens Y. Humrich   +10 more
wiley   +1 more source

Correction: Efficacy and safety of mesenchymal stem cell transplantation for progressive multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials with clinical implications for patient stratification and treatment optimization. [PDF]

Front Immunol
Guo H, Zeng L, Sun L.
europepmc   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source